Biotech News
Related news
LYELLyell Immunopharma2026-08-06 20:05 EST
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
IMVTImmunovant2026-08-06 11:00 EST
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
BMEABiomea Fusion2026-08-05 20:05 EST
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
ELVNEnliven Therapeutics2026-08-05 20:05 EST
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
KURAKura Oncology2026-08-05 11:30 EST
Kura Oncology to Report Second Quarter Financial Results
RVMDRevolution Medicines2026-07-29 20:05 EST
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
SNDXSyndax Pharmaceuticals2026-07-28 11:00 EST
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
IMVTImmunovant2026-07-23 20:05 EST
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
CHRSCoherus BioSciences, Inc.2026-07-22 17:36 EST
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
REPLReplimune Group2026-06-29 12:00 EST
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
Vaccinex
Vaccinex is a biotechnology company focused on antibody therapies and immunology, with a history of pursuing difficult oncology and neurodegenerative targets. Its story is tied to platform science and the challenge of turning it into durable value.
Recent company news
VCNXVaccinex2026-04-30 00:05 EST
Vaccinex Reports 2025 Annual Financial Results
VCNXVaccinex2025-12-23 13:01 EST
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
VCNXVaccinex2025-05-27 12:45 EST
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
VCNXVaccinex2025-04-21 12:45 EST
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
VCNXVaccinex2025-03-07 22:15 EST
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
Stock data
- Close
- 0.78 USD
- Market cap
- —
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States